Pyxis Oncology (PYXS) Cash from Investing Activities (2021 - 2025)

Pyxis Oncology (PYXS) has 5 years of Cash from Investing Activities data on file, last reported at $16.3 million in Q4 2025.

• Cash from Investing Activities for Q4 2025 came in at $16.3 million, down 39.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $58.9 million (up 621.73% YoY), and the FY2025 annual result was $58.9 million, up 621.73% from the prior year.
• Cash from Investing Activities advanced to $16.3 million in Q4 2025 per PYXS's latest filing, from $11.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $26.7 million in Q4 2024 and troughed at -$99.4 million in Q1 2023.
• A 5-year average of -$2.5 million and a median of -$68500.0 in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities sank 67977.4% in 2023, then surged 382500.0% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$371000.0 in 2021, then slumped by 400.81% to -$1.9 million in 2022, then surged by 650.48% to $10.2 million in 2023, then surged by 160.63% to $26.7 million in 2024, then tumbled by 39.0% to $16.3 million in 2025.
• Business Quant data shows PYXS's Cash from Investing Activities at $16.3 million in Q4 2025, $11.5 million in Q3 2025, and $15.3 million in Q2 2025.